Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q1 2017 Earnings Presentation
10 slides from Agilent Technologies's earnings presentation, Feb 14, 2017
Slide 1: Agilent Technologies Q1'17 Results Presentation
Agilent Technologies Q1'17 Results Presentation
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company’s goals, priorities, revenues, operating profit and operating margin, growth opportunities, customer service and innovation plans, new product introduction
Slide 3: Agilent Results Q1'17
Agilent Results Q1'17 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q1'17 Financial Metrics Q1'17 Headlines • Revenues: $1.07B, +4.8% y/y core(1)(2),+3.8% • Growth: Core growth across all businesses and reported (-1.0% FX). Growth in Food and geographies offse
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) Instrumentation and Informatics • Solid core revenue growth across regions for Analytical Laboratories with strength in Asia. Pharma, Food and Chem&Energy gains partially offset by softness in A&G and Forensics. Momentum in LC, GCMS, and Informatics. • Op
Slide 5: Agilent Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) Analytical Laboratory • Continued momentum with growth led by Consumables and Services Food and Pharma. Gains across all regions led by expansion in Asia. Strength in Contract Services and LC Columns. • Operating Margin in the quarter was 20.3%(1)(2), down 180 bps versu
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) Pathology, Genomics, and • Solid growth performance led by strength in Nucleic Acid Manufacturing Companion Diagnostics and Nucleic Acid Solutions. Americas and Europe led regional gains. • Operating Margin for the quarter was 14.3%(1)(2), up 470 bps versus last
Slide 7: Growth in a $50B Market – Q1'17 Results by End Market
Growth in a $50B Market – Q1'17 Results by End Market Mixed performance led again by Pharma, Food, and Diagnostics/Clinical plus growth in Chemical/Energy. Partially offset by soft Academic/Government and Forensics. Analytical Laboratory End Markets Agilent Revenue by End Market (1) Q1'17 revenues
Slide 8: Profitable Growth Plan
Agilent Profitable Growth Plan Recent Actions Delivering on “Agile Agilent” Initiatives • Multi-year program to increase efficiency and customer focus. • Operating Margin up year-over-year – 8th consecutive quarter. • Launched eRenewals, a first-in-the industry program to enable paperless renewals
Slide 9: Strategy to Win
Agilent Strategy to Win Creating shareholder value Above Market Growth • Win enterprise lab-wide services & consumables - CrossLab • Accelerate bio-pharma penetration • Drive adoption of clinical genomics applications Aggressively expand operating margins • FY17 adjusted Operating Margin guidanc
Slide 10: Q2'17 and FY17 Guidance and Forward-looking Considerations
Q2’17 and FY17 Guidance and Forward-looking Considerations Based on January 31, 2016 Exchange Rates FY17 FY17 Guidance FY16 Guidance at • Revenue: $4.33B - $4.35B: growth at mid-point 4.5% core(4), 3.3% (2) mid-point Actual reported (1) (+0.2% M&A, -1.4% FX) (1)(2) • Operating Margin: 20.9% at mid-p